Funding to stop Candida auris lacking

A high proportion of people who have been diagnosed with C. auris have died


Scientists who work in mycology — the study of fungi — say there is precious little money available to study Candida auris, according to an article on the STAT News website.

Candida auris is making news for its ability to resist multiple antifungal drugs and settle into hospital rooms so persistently it can take renovations to get rid of it.

The head of mycotic diseases at the Centers for Disease Control and Prevention (CDC) acknowledged his field hasn’t attracted the same kind of research dollars as other pathogens.

A high proportion of people who have been diagnosed with C. auris have died — the CDC estimates it’s between 30 percent and 60 percent.

Read the article.



July 16, 2019


Topic Area: Infection Control


Recent Posts

Hand, Foot and Mouth Disease on the Rise

A number of states are reporting an uptick in HFMD, a highly contagious viral illness that primarily affects infants and young children.


Preparing for the Hazards of Winter Weather

Winter is here and healthcare facilities must be ready for inclement weather to prevent slips and falls.


BayCare Reveals Pagidipati Children's Hospital at St. Joseph's

It is a freestanding facility scheduled to open in 2030.


Why Identity Governance Is Becoming a Facilities Management Issue

As healthcare buildings grow more connected, weak identity controls can expose HVAC, security and other critical systems to serious risk.


Habitat Health Opens South Los Angeles PACE Center

The new center strengthens the local care infrastructure, delivering integrated medical, social and in-home care.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.